MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model

BACKGROUND: Renal cell carcinoma (RCC) patients treated with tyrosine kinase inhibitors (TKI) typically respond initially, but usually develop resistance to therapy. We utilised transcriptome analysis to identify gene expression changes during development of sunitinib resistance in a RCC patient-der...

Descripción completa

Detalles Bibliográficos
Autores principales: Diaz-Montero, C Marcela, Mao, Frances J, Barnard, John, Parker, Yvonne, Zamanian-Daryoush, Maryam, Pink, John J, Finke, James H, Rini, Brian I, Lindner, Daniel J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061902/
https://www.ncbi.nlm.nih.gov/pubmed/27560553
http://dx.doi.org/10.1038/bjc.2016.263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061902/
https://www.ncbi.nlm.nih.gov/pubmed/27560553
http://dx.doi.org/10.1038/bjc.2016.263

Ejemplares similares